Announcements Trials

Browse Landscape

Phase

Phase 1/2 18 Phase 1 13 Phase 2 7 Phase NA 1 Phase EARLY_PHASE1 1 Phase 3 1

Status

Completed 4 Unknown 2 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Magnetic Resonance Spectroscopy 17 Cyclophosphamide 16 fludarabine 12 Specimen Handling 12 Fluorodeoxyglucose F18 7 pembrolizumab 6 X-Rays 6 Nivolumab 6 Temozolomide 5 Radiotherapy 5 Immunotherapy, Adoptive 5 lenvatinib 4 Paclitaxel 4 Leukapheresis 4 Immune Checkpoint Inhibitors 4 Etoposide 4 Cisplatin 4 Carboplatin 4 ruxolitinib 3 fluciclovine F-18 3 Tirzepatide 3 Surgical Procedures, Operative 3 Doxorubicin 3 Dasatinib 3 Cholecalciferol 3 Biopsy 3 68Ga-FAPI 3 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3 tislelizumab 2 palbociclib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Recruiting × Interleukin-2 × Clear all

NCT05141474 2024-11-07

NEXTGENTIL-ACT

Vall d'Hebron Institute of Oncology

Phase EARLY_PHASE1 Recruiting

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡